MIMEDX delivered a solid first quarter for 2025 with 4% year-over-year net sales growth driven by strong performance in surgical products. While facing setbacks with LCDs, the company is strategically adding new products to navigate the reimbursement landscape and remains focused on expanding the use cases for its proprietary technology.
Net sales for Q1 2025 were $88 million, a 4% increase compared to the prior year.
Surgical products experienced significant growth of 16% in the first quarter.
GAAP Net Income and Earnings Per Share for Q1 were $7 million and $0.05, respectively.
Adjusted EBITDA for the first quarter was $17.2 million, representing a margin of 19.5%.
MIMEDX expects net sales growth for 2025 to be at least in the high single-digits and anticipates a full-year Adjusted EBITDA margin above 20%. The company is focused on expanding use cases for its technology and introducing new products.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance